In a retrospective analysis, Jurgensmeier et al. discussed “Cediranib with fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer” (HORIZON III), a randomized controlled trial, concluding that high baseline VEGF values are associated with worse Progression-Free Survival (PFS) and Overall Survival (OS) in mCRC patients, independent of treatment [15]. This evidence concerns the gene VEGFA and colorectal cancer.